ZA201206469B - (r)-4((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]soxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol,a partial agonist of 5-ht4 receptors - Google Patents

(r)-4((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]soxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol,a partial agonist of 5-ht4 receptors

Info

Publication number
ZA201206469B
ZA201206469B ZA2012/06469A ZA201206469A ZA201206469B ZA 201206469 B ZA201206469 B ZA 201206469B ZA 2012/06469 A ZA2012/06469 A ZA 2012/06469A ZA 201206469 A ZA201206469 A ZA 201206469A ZA 201206469 B ZA201206469 B ZA 201206469B
Authority
ZA
South Africa
Prior art keywords
yloxy
methyl
soxazol
pyran
piperidin
Prior art date
Application number
ZA2012/06469A
Other languages
English (en)
Inventor
Hirohide Noguchi
Nobuaki Waizumi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA201206469B publication Critical patent/ZA201206469B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2012/06469A 2010-02-16 2012-08-28 (r)-4((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]soxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol,a partial agonist of 5-ht4 receptors ZA201206469B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30492110P 2010-02-16 2010-02-16
PCT/IB2011/050548 WO2011101774A1 (en) 2010-02-16 2011-02-09 (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors

Publications (1)

Publication Number Publication Date
ZA201206469B true ZA201206469B (en) 2013-05-29

Family

ID=43904611

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/06469A ZA201206469B (en) 2010-02-16 2012-08-28 (r)-4((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]soxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol,a partial agonist of 5-ht4 receptors

Country Status (15)

Country Link
US (1) US20120041026A1 (OSRAM)
EP (1) EP2536713A1 (OSRAM)
JP (1) JP2013519722A (OSRAM)
KR (1) KR20120123089A (OSRAM)
CN (1) CN102762554A (OSRAM)
AR (1) AR080172A1 (OSRAM)
AU (1) AU2011216950A1 (OSRAM)
CA (1) CA2788656A1 (OSRAM)
IN (1) IN2012DN06631A (OSRAM)
MX (1) MX2012008721A (OSRAM)
SG (1) SG183111A1 (OSRAM)
TW (1) TW201141856A (OSRAM)
UY (1) UY33225A (OSRAM)
WO (1) WO2011101774A1 (OSRAM)
ZA (1) ZA201206469B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20190015614A (ko) 2011-05-18 2019-02-13 라퀄리아 파마 인코포레이티드 4-｛[4-(｛[4-(2,2,2-트리플루오로에톡시)-1,2-벤즈이속사졸-3-일]옥시｝메틸)피페리딘-1-일]메틸｝-테트라히드로-2h-피란-4-카르복실산의 다형
HK1208457A1 (en) * 2012-11-21 2016-03-04 拉夸里亚创药株式会社 Polymorph forms
DK2976337T3 (en) 2013-03-20 2018-07-16 Suven Life Sciences Ltd 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
EP3099675B1 (en) 2013-12-16 2018-02-14 Suven Life Sciences Limited Indazole compounds as 5-ht4 receptor agonists
WO2015178020A1 (en) * 2014-05-20 2015-11-26 Raqualia Pharma Inc. Benzisoxazole derivative salt
HUE045667T2 (hu) 2015-02-13 2020-01-28 Suven Life Sciences Ltd Amidvegyületek 5-HT4 receptor agonistaként
CN117796401A (zh) * 2023-12-25 2024-04-02 江苏万隆化学有限公司 一种含2-羟基-6-氟苯甲酸甲酯中间体抗菌剂的制备工艺

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE137225T1 (de) 1991-02-27 1996-05-15 Merrell Pharma Inc Dihydrochinolin nmda antagonisten
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
FI952481L (fi) * 1992-11-23 1995-05-22 Hoechst Roussel Pharma Substituoituja 3-(aminoalkyyliamino)-1,2-bentsisoksatoleja ja niihin liittyviä yhdisteitä
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
EP0854867B1 (en) 1995-09-29 2002-07-31 GLAXO WELLCOME S.p.A. Tetrahydroquinolines as nmda antagonists
IL126003A0 (en) 1996-04-10 1999-04-11 Hoechst Marion Roussel Inc Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors
BR9708655A (pt) 1996-04-12 1999-08-03 Hoechst Marion Roussel Inc Derivados de isatina como inibidores de acetilcolinesterase e analgésicos
CA2258044C (en) 1996-07-01 2007-09-04 Schering Corporation Muscarinic antagonists
CA2263167C (en) 1996-08-15 2006-02-14 Schering Corporation Ether muscarinic antagonists
NZ334343A (en) 1996-09-30 2001-01-26 Hoechst Marion Roussel Inc NMDA (n-methyl-d-aspartate) antagonists which preferentially bind to the strychnine-insensitive glycine binding site on the NMDA receptor complex
AU758802B2 (en) 1998-09-30 2003-03-27 Takeda Pharmaceutical Company Limited Drugs for improving vesical excretory strength
ES2299561T3 (es) 2001-01-26 2008-06-01 Btg International Limited Analogo de bencilamina.
CA2440284A1 (en) 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
JP2005511478A (ja) 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
HRP20040178B1 (hr) 2001-07-24 2013-05-31 Richter Gedeon Vegyészeti Gyár RT Derivati piperidina kao antagonisti nmda receptora
CN1798744A (zh) 2003-06-04 2006-07-05 麦克公司 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
GB0316094D0 (en) 2003-07-09 2003-08-13 Neuropharma Sa Acetylcholinesterase dual inhibitors
DK2656859T3 (en) * 2004-03-03 2016-01-11 Revance Therapeutics Inc Topical application and transdermal delivery of the botulinum toxins
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
HU227000B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
TW200621677A (en) 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
AU2004324030B2 (en) 2004-10-15 2012-09-06 Universidade Estadual Paulista-Unesp Piperidinic derivatives, pharmaceutic compositions containing the same and preparation processes
JP4970290B2 (ja) * 2005-02-25 2012-07-04 ファイザー株式会社 ベンズイソキサゾール誘導体
US20090124600A1 (en) 2005-04-19 2009-05-14 Layton Mark E N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
US20090258824A1 (en) 2005-07-29 2009-10-15 Ashe Karen H Amyloid beta receptor and uses thereof
EP2001463B1 (en) 2006-03-20 2013-07-03 Council of Scientific and Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
ES2288406B1 (es) 2006-04-20 2008-12-16 Universidad De Barcelona Compuestos inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
DE602007013275D1 (de) 2006-12-20 2011-04-28 Abbott Healthcare Products Bv Verbindungen mit kombinierten cannabinoid-cb1-antagonismus und acetylcholinesterasehemmung
US7605265B2 (en) 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
CN101687868B (zh) 2007-05-01 2012-12-12 康塞特医药品公司 吗啡烷化合物
CN104844678B (zh) 2007-05-11 2018-02-09 香港科技大学 具有神经保护和增强记忆活性的受体调节剂
EA201070077A1 (ru) 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
CA2699412A1 (en) 2007-09-12 2009-03-19 Virginia Tech Intellectual Properties, Inc. Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache)
GB2470495B (en) 2008-01-16 2012-12-26 Biotechnology Res Corp Ltd Oxazolidine derivatives as NMDA antagonists
EA014100B1 (ru) 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
CN101440061B (zh) 2008-04-08 2010-12-08 温州医学院 一类具有抑制乙酰胆碱酯酶活性的芳基吡啶酮类衍生物
WO2009129181A1 (en) 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
SG195568A1 (en) 2008-05-09 2013-12-30 Univ Emory Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Also Published As

Publication number Publication date
TW201141856A (en) 2011-12-01
WO2011101774A1 (en) 2011-08-25
EP2536713A1 (en) 2012-12-26
MX2012008721A (es) 2012-08-17
SG183111A1 (en) 2012-09-27
KR20120123089A (ko) 2012-11-07
JP2013519722A (ja) 2013-05-30
AU2011216950A1 (en) 2012-08-23
IN2012DN06631A (OSRAM) 2015-10-23
CA2788656A1 (en) 2011-08-25
AR080172A1 (es) 2012-03-21
US20120041026A1 (en) 2012-02-16
CN102762554A (zh) 2012-10-31
UY33225A (es) 2011-09-30

Similar Documents

Publication Publication Date Title
ZA201206469B (en) (r)-4((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]soxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol,a partial agonist of 5-ht4 receptors
HUS2200033I1 (hu) CGRP receptor antagonisták
GB2463788B (en) Heteroaryl antagonists of prostaglandin D2 receptors
ATE539056T1 (de) Piperidinderivate als agonisten muskariner rezeptoren
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
PT2826776T (pt) Forma amorfa sólida de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-ilo)-n-(1-(2,3-dihidroxipropilo)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-ilo)-1h-indol-5-ilo)-ciclopropanocarboxamida
IL220155B (en) History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors
GB2461629B (en) Antagonists of prostaglandin D2 receptors
SI2593452T1 (sl) Heterociklične spojine agonisti receptorja IP
EP2245022A4 (en) ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
BR112012002336A2 (pt) compostos aza-heterocíclicos
ZA200904289B (en) Polymorphs of a Mglur5 receptor antagonist
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
IL213982A0 (en) Piperidine derivatives as nk3 receptor antagonists
EP2271346A4 (en) MONOCYCLIC CGRP RECEPTOR ANTAGONISTS
IL207577A0 (en) Pyrrolidine ether derivatives as nk3 receptor antagonists
EP2365748A4 (en) IMIDAZOISOINDOL neuropeptide S RECEPTOR ANTAGONISTS
IL220554A (en) History of aminoalkylpyrimidine as histamine receptor antagonists 4h
EP2578569A4 (en) HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST
IL213769A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
ME01748B (me) Novi derivati sekundarnog 8- hidroksihinolin-7 karboksamida
ZA201109451B (en) Imidazole derivatives as mglur5 antagonists
TWM370921U (en) Innovation structure of drilling machine for betel nut
HK1168355A (en) Novel fumarate salts of a histamine h3 receptor antagonist